BioSpace News Archive

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”) today announced preclinical data demonstrating the Company’s lead drug candidate GT-02287 significantly decreased Parkinson’s disease (PD)-associated pathology and improved motor dysfunction in two different preclinical models of Parkinson’s disease.

Bio-Techne Corporation announced that it will present at the following investor healthcare conferences.

CSL Vifor is pleased to announce that the European Society of Cardiology have upgraded recommendations in the ESC 2023 guidelines for the treatment of iron deficiency acute and chronic HF with IV iron supplementation, including Ferinject®.

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the full commercial launch and successful completion of the first cases in the U.S. with the 7D FLASH™ Navigation System Percutaneous Module 2.0.

Centene Corporation announced that it has signed a definitive agreement to sell Circle Health Group, one of the U.K.'s largest independent operators of hospitals, to PureHealth, the largest integrated healthcare network in the Middle East.

HanchorBio Inc. and Shanghai Henlius Biotech, Inc. today announced that the two companies have entered into a strategic framework agreement for collaboration to combine HanchorBio’s protein engineering expertise and proprietary Fc-based designer biologics (FBDB™) technology platform with Henlius’ integrated product development and commercialization capabilities.

NLS Pharmaceutics Ltd. announced that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders.

HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies.

SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, announced that management will participate in the following investor conferences.

Collegium Pharmaceutical, Inc. announced that 10 poster presentations highlighting data regarding its diversified pain portfolio will be presented at PAINWeek Conference 2023, being held in Las Vegas, NV from September 5–8, 2023.